Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model

被引:31
|
作者
Kuramoto, Emi
Nishiuma, Teruaki
Kobayashi, Kazuyuki
Yamamoto, Masatsugu
Kono, Yuko
Funada, Yasuhiro
Kotani, Yoshikazu
Sisson, Thomas H. [2 ]
Simon, Richard H. [2 ]
Nishimura, Yoshihiro [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med,Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA
关键词
urokinase; plasmin; bronchial asthma; subepithelial fibrosis; HEPATOCYTE GROWTH-FACTOR; INDUCED PULMONARY-FIBROSIS; INDUCED LUNG FIBROSIS; TGF-BETA; INFLAMMATION; INHIBITOR-1; EXPRESSION; COLLAGEN; MICE; ACCUMULATION;
D O I
10.1152/ajplung.90434.2008
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Kuramoto E, Nishiuma T, Kobayashi K, Yamamoto M, Kono Y, Funada Y, Kotani Y, Sisson TH, Simon RH, Nishimura Y. Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model. Am J Physiol Lung Cell Mol Physiol 296: L337-L346, 2009. First published December 19, 2008; doi: 10.1152/ajplung.90434.2008.-The airway remodeling that occurs in asthma is characterized by an excess of extracellular matrix deposition in the submucosa, hyperplasia/hypertrophy of smooth muscle, goblet cell metaplasia, and accumulation of fibroblasts/myofibroblasts. he urokinase-type plasminogen activator (uPA)/plasmin system participates in pericellular proteolysis and is capable of directly degrading matrix components, activating latent proteinases, and activating growth factors. In a mouse ovalbumin (OVA) asthma model, we increased plasminogen activator activity in the lung by administering exogenous uPA or by using mice genetically deficient in the uPA inhibitor plasminogen activator inhibitor-1 (PAI-1) to assess the role of this system in asthma pathogenesis. After intraperitoneal OVA sensitization, mice inhaled OVA plus uPA (500 IU/mouse) or saline by ultrasonic nebulization for 3 wk. When studied 24 h after the final exposure, the groups with upregulated plasmin activity had significantly reduced subepithelial fibrosis within the airway walls and had decreased airway hyperresponsiveness (AHR) to methacholine. Morphometric analysis showed that subepithelial wall thickening of the bronchi (subepithelial area ratio) was also reduced, as were collagen and alpha-smooth muscle actin. Upregulation of plasmin activity also increased the level of hepatocyte growth factor activity in bronchoalveolar lavage fluid, whereas the release of transforming growth factor-beta was decreased. The administration of uPA 1 wk after the last OVA inhalation also significantly reduced lung hydroxyproline content and AHR. These results show that enhancing uPA/plasmin activity lessens the airway remodeling in a murine asthma model.
引用
收藏
页码:L337 / L346
页数:10
相关论文
共 50 条
  • [21] Urokinase-type plasminogen activator inhibitors.
    Squires, N
    McGee, D
    Allen, D
    Hruzewicz, W
    Spencer, J
    Sprengeler, P
    Katz, B
    Luong, C
    Mackman, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U51 - U51
  • [22] Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator
    Jo, MJ
    Thomas, KS
    Marozkina, N
    Amin, TJ
    Silva, CM
    Parsons, SJ
    Gonias, SL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (17) : 17449 - 17457
  • [23] Transcriptional regulation of the murine urokinase-type plasminogen activator gene in skeletal myoblasts
    Miralles, F
    Ibáñez-Tallon, I
    Parra, M
    Crippa, M
    Blasi, F
    Besser, D
    Nagamine, Y
    Muñoz-Cánoves, P
    THROMBOSIS AND HAEMOSTASIS, 1999, 81 (05) : 767 - 774
  • [24] Multiparity upregulates placental plasminogen and urokinase-type plasminogen activator
    Cortina, Maria E.
    Litwin, Silvana
    Hawila, Maria R. Rial
    Miranda, Silvia
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2017, 77 (04)
  • [25] Plasminogen activator inhibitor-1 promotes airway remodeling in a murine model of chronic asthma
    Oh, CK
    Ariue, B
    Alban, RF
    Cho, SH
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) : S32 - S32
  • [26] Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system
    Yin, SP
    Lockett, J
    Meng, YH
    Biliran, H
    Blouse, GE
    Li, XH
    Reddy, N
    Zhao, ZM
    Lin, XL
    Anagli, J
    Cher, ML
    Sheng, SJ
    CANCER RESEARCH, 2006, 66 (08) : 4173 - 4181
  • [27] Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B
    Zhou, Huanqin
    Wu, Xianguo
    Lu, Xingguo
    Chen, Gang
    Ye, Xiongwei
    Huang, Jian
    THROMBOSIS RESEARCH, 2009, 123 (03) : 537 - 542
  • [28] Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke
    Nagai, Nobuo
    Okada, Kiyotaka
    Kawao, Naoyuki
    Shida, Chikako
    Ueshima, Shigeru.
    Collen, Desire
    Matsuo, Osamu
    NEUROSCIENCE LETTERS, 2008, 432 (01) : 46 - 49
  • [29] Amiloride, a urokinase-type plasminogen activator receptor (uTPA) inhibitor, reduces proteinurea in podocytes
    Xu, L. B.
    Chi, N.
    Shi, W.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (03) : 9518 - 9529
  • [30] Urokinase-type plasminogen activator receptor: A beacon of malignancy?
    Drapkin, Ronny
    Clauss, Adam
    Skates, Steven
    CLINICAL CANCER RESEARCH, 2008, 14 (18) : 5643 - 5645